ProfileGDS4814 / ILMN_1765649
TitleOvarian cancer xenograft tumor response to trastuzumab and pertuzumab
OrganismHomo sapiens


none trastuzumab pertuzumab trastuzumab and pertuzumab GSM780707 GSM780708 GSM780709 GSM780719 GSM780720 GSM780721 GSM780710 GSM780711 GSM780712 GSM780722 GSM780723 GSM780724 GSM780713 GSM780714 GSM780715 GSM780725 GSM780726 GSM780727 GSM780716 GSM780717 GSM780718 GSM780728 GSM780729 85% 84% 84% 86% 85% 83% 84% 85% 86% 84% 85% 85% 85% 84% 86% 86% 85% 85% 86% 84% 85% 86% 85% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM780707Untreated after 4 days (C1_1)231.08685
GSM780708Untreated after 4 days (C2_1)199.77784
GSM780709Untreated after 4 days (C3_1)212.41184
GSM780719Untreated after 4 days (C1_2)269.60686
GSM780720Untreated after 4 days (C2_2)231.2285
GSM780721Untreated after 4 days (C3_2)197.78983
GSM780710Trastuzumab treated after 4 days (T1_1)200.88384
GSM780711Trastuzumab treated after 4 days (T2_1)235.24885
GSM780712Trastuzumab treated after 4 days (T3_1)253.37186
GSM780722Trastuzumab treated after 4 days (T1_2)203.08784
GSM780723Trastuzumab treated after 4 days (T2_2)224.7585
GSM780724Trastuzumab treated after 4 days (T3_2)235.13285
GSM780713Pertuzumab treated after 4 days (P1_1)242.00485
GSM780714Pertuzumab treated after 4 days (P2_1)199.1784
GSM780715Pertuzumab treated after 4 days (P3_1)247.87686
GSM780725Pertuzumab treated after 4 days (P1_2)263.32586
GSM780726Pertuzumab treated after 4 days (P2_2)233.12885
GSM780727Pertuzumab treated after 4 days (P3_2)228.15385
GSM780716Trastuzumab and Pertuzumab treated after 4 days (TP1_1)259.01786
GSM780717Trastuzumab and Pertuzumab treated after 4 days (TP2_1)215.4384
GSM780718Trastuzumab and Pertuzumab treated after 4 days (TP3_1)233.03785
GSM780728Trastuzumab and Pertuzumab treated after 4 days (TP1_2)250.86386
GSM780729Trastuzumab and Pertuzumab treated after 4 days (TP2_2)221.01885